Sentinel lymph node biopsy before or after neoadjuvant chemotherapy: Pros and Cons

Surgical Oncology Clinics of North America

Volumn 19, Issue 3, 2010, Pages 519-538

  Sabel, Michael S ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Sentinel lymph node biopsy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ACCURACY; ADJUVANT THERAPY; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; HUMAN; LYMPH NODE DISSECTION; MASTECTOMY; MICROMETASTASIS; MORBIDITY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PATIENT SAFETY; PREDICTION; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; BREAST TUMOR; FEMALE; LYMPH NODE; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; NEOADJUVANT THERAPY; SENTINEL LYMPH NODE BIOPSY;

EID: 77954149105     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2010.03.004     Document Type: Review

References (109)

1. Chung M.H., Ye W., Giuliano A.E. Role for sentinel lymph node dissection in the management of large (>5cm) invasive breast cancer. Ann Surg Oncol 2001, 8(9):688-692.
2. Bedrosian I., Reynolds C., Mick R., et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 2000, 88:2540-2545.
3. Paik S, Shak S, Tang G, et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients- NSABP studies B20 and B14. 26th Annual San Antonio Breast Cancer Symposium. Vol. Abstract #16. San Antonio (TX), December 3-6, 2003.
4. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
5. Hayes D.F., Thor A.D., Dressler L.G., et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007, 357:1496-1506.
6. Albain K.S., Barlow W., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100) [abstract 10]. Breast Cancer Res Treat 2007, 106(Suppl 1).
7. Straver M.E., Rutgers E.J.T., Russel N.S., et al. Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer. Eur J Cancer 2009, 45:2284-2292.
8. Rouzier R., Extra J.-M., Klijanienko J., et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002, 20(5):1304-1310.
9. Newman E.A., Sabel M.S., Nees A.V., et al. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol 2007, 14(10):2946-2952.
10. Hennessy B.T., Hortobagyi G.N., Rouzier R., et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005, 23(36):9304-9311.
11. Beatty J.D., Precht L.M., Lowe K., et al. Axillary-conserving surgery is facilitated by neoadjuvant chemotherapy of breast cancer. Am J Surg 2009, 197:637-642.
12. Van Zee K.J., Manasseh D.M., Bevilacqua J.L., et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003, 10:1140-1151.
13. Degnim A.C., Reynolds C., Pantvaidya G., et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg 2005, 190(4):543-550.
14. Bilimoria K.Y., Bentrem D.J., Hansen N.M., et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009, 27(18):2946-2953.
15. Evrensel T., Johnson R., Ahrendt G., et al. The predicted probability of having positive non-sentinel lymph nodes in patients who received neoadjuvant chemotherapy for large operable breast cancer. Int J Clin Pract 2007, 62(9):1379-1382.
16. Jeruss J.S., Newman L.A., Ayers G.D., et al. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. Cancer 2008, 112:2646-2654.
17. Torisu-Itakura H., Lee J.H., Scheri R.P., et al. Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma. Clin Cancer Res 2007, 13(11):3125-3132.
18. Specht M.C., Fey J.V., Borgen P.I., et al. Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy?. J Am Coll Surg 2005, 200(1):10-14.
19. Oruwari J.U., Chung M.A., Koelliker S., et al. Axillary staging using ultrasound-guided fine needle aspiration biopsy in locally advanced breast cancer. Am J Surg 2002, 184:307-309.
20. Krishnamurthy S., Sneige N., Bedi D.G., et al. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer 2002, 95:982-988.
21. de Kanter A.Y., van Eijck C.H.J., van Geel A.N., et al. Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer. Br J Surg 1999, 86(11):1459-1462.
22. Lam W.W., Yang W.T., Chan Y.T., et al. Detection of axillary lymph node metastases in breast carcinoma by technetium-99m sestamibi breast scintigraphy, ultrasound, and conventional mammography. Eur J Nucl Med 1996, 23(5):498-503.
23. Bonnema J., van Geel A.N., van Ooijen B., et al. Ultrasound-guided aspiration biopsy for detection of nonpalpable axillary node metastases in breast cancer patients: new diagnostic method. World J Surg 1997, 21(3):270-274.
24. Ciatto S., Brancato B., Risso G., et al. Accuracy of fine needle aspiration cytology (FNAC) of axillary lymph nodes as a triage test in breast cancer staging. Breast Cancer Res Treat 2007, 103:85-91.
25. Shen J., Gilcrease M.Z., Babiera G.V., et al. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 2007, 109:1255-1263.
26. Lee S., Kim E.Y., Kang S.H., et al. Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients. Breast Cancer Res Treat 2007, 102:283-288.
27. Xing Y., Foy M., Cox D.D., et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 2006, 93:539-546.
28. Mamounas E.P., Bellon J.R. Local-regional therapy considerations in patients receiving preoperative chemotherapy. Diseases of the breast 2010, 730-744. Lippincott Williams & Wilkins, Philadelphia. 4th edition. J.R. Harris, M.E. Lippman, M. Morrow, et al (Eds.).
29. Mamounas E.P., Brown A., Anderson S., et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005, 23(12):2694-2702.
30. Krag D., Weaver D., Ashikaga T., et al. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med 1998, 339(14):941-946.
31. Lyman GH, Kim TY, Giuliano AE. A systematic review and meta-analysis of lymphatic mapping and sentinel node biopsy (SNB) in early stage breast cancer [abstract 2001]. San Antonio Breast Conference. San Antonio (TX), December 2-11, 2004.
32. Fraile M., Rull M., Julian F.J., et al. Sentinel node biopsy as a practical alternative to axillary lymph node dissection in breast cancer patients: an approach to its validity. Ann Oncol 2000, 11:701-705.
33. Miltenburg D.M., Miller C., Karamlou T.B., et al. Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res 1999, 84:138-142.
34. Julian TB, Krag DN, Brown A, et al. Preliminary technical results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients [abstract 14]. San Antonio Breast Cancer Symposium. San Antonio (TX), December 2-11, 2004.
35. Sabel M.S., Zhang P., Barnwell J.M., et al. Accuracy of sentinel node biopsy in predicting nodal status in patients with breast carcinoma. J Surg Oncol 2001, 77(4):243-246.
36. Chu K.U., Turner R.R., Hansen N.M., et al. Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis. Ann Surg Oncol 1999, 6(8):756-761.
37. Fant J.S., Grant M.D., Knox S.M., et al. Preliminary outcome in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol 2003, 10:126-130.
38. Zakaria S., Pantivaidya G., Reynolds C.A., et al. Sentinel node positive breast cancer patients who do not undergo axillary dissection: are they different?. Surgery 2007, 143(5):641-647.
39. Jeruss J.S., Winchester D.J., Sener S.F., et al. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol 2005, 12:34-40.
40. Guenther J.M., Hansen N.M., DiFronzo L.A., et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg 2003, 138:52-56.
41. Sabel M.S. Locoregional therapy of breast cancer: maximizing control, minimizing morbidity. Expert Rev Anticancer Ther 2007, 6(9):1261-1279.
42. Hunt K.K., Yi M., Mittendorf E.A., et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg 2009, 250(4):558-566.
43. Klauber-Demore N., Ollila D.W., Moore D.T., et al. Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic. Ann Surg Oncol 2006, 13(5):685-691.
44. Overgaard M., Hansen P.S., Overgaard J., et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997, 337(14):949-955.
45. Overgaard M., Jensen M.B., Overgaard J., et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999, 353:1641-1648.
46. Ragaz J., Jackson S.M., Le N., et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997, 337:956-962.
47. Buchholz T.A., Tucker S.L., Masullo L., et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 2002, 20(1):17-23.
48. McGuire S.E., Gonzalez-Angulo A.M., Huang E.H., et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2007, 68:1004-1009.
49. Kilbride K.E., Lee M.C., Nees A.V., et al. Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence. Ann Surg Oncol 2008, 15(11):3252-3258.
50. Zirngibl C., Steinfeld-Birg D., Vogt H., et al. Sentinel lymph node biopsy before neoadjuvant chemotherapy-conservation of breast and axilla [abstract]. Breast Cancer Res Treat 2002, 76(Suppl 1):S129.
51. Schrenk P., Hochreiner G., Fridrik M., et al. Sentinel node biopsy performed before preoperative chemotherapy for axillary lymph node staging in breast cancer. Breast J 2003, 9(4):282-287.
52. Sabel M.S., Schott A.F., Kleer C.G., et al. Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg 2003, 186(2):102-105.
53. Ollila D.W., Neuman H.B., Sartor C., et al. Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers. Am J Surg 2005, 190:371-375.
54. Jones J.L., Zabicki K., Christian R.L., et al. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important. Am J Surg 2005, 190(4):517-520.
55. van Rijk M.C., Nieweg O.E., Rutgers E.J.T., et al. Sentinel node biopsy before neoadjuvant chemotherapy spares breast cancer patients axillary lymph node dissection. Ann Surg Oncol 2006, 13(4):475-479.
56. Cox C.E., Cox J.M., White L.B., et al. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. Ann Surg Oncol 2006, 13(4):483-490.
57. Grube B.J., Christy C.J., Black D., et al. Breast sentinel lymph node dissection before preoperative chemotherapy. Arch Surg 2008, 143(7):692-700.
58. Papa M.Z., Zippel D., Kaufman B., et al. Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer. J Surg Oncol 2008, 98:403-406.
59. Cohen L.F., Breslin T.M., Keurer H.M., et al. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol 2000, 24(9):1266-1272.
60. Breslin T.M., Cohen L.F., Sahin A.A., et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000, 18(20):3480-3486.
61. Nason K.S., Anderson B.O., Byrd D.R., et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000, 89(11):2187-2194.
62. Fernandez A., Cortes M., Benito E., et al. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun 2001, 22:361-366.
63. Tafra L., Verbanac K.M., Lannin D.R. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg 2001, 182:312-315.
64. Stearns V., Ewing C.A., Slack R., et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002, 9(3):235-242.
65. Brady E.W. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Breast J 2002, 8(2):97-100.
66. Julian T.B., Dusi D., Wolmark N. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 2002, 184(4):315-317.
67. Miller A.R., Thomason V.E., Yeh I.-T., et al. Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol 2002, 9(3):243-247.
68. Vigario A., Sapienza M.T., Sampaio A.P., et al. Primary chemotherapy effect in sentinel node detection in breast cancer. Clin Nucl Med 2003, 28(7):553-557.
69. Balch G.C., Mithani S.K., Richards K.R., et al. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol 2003, 10:616-621.
70. Reitsamer R., Peintiger F., Rettenbacher L., et al. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy. J Surg Oncol 2003, 84:63-67.
71. Schwartz G.F., Meltzer A.J. Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast. Breast J 2003, 9:374-379.
72. Piato J.R., Barros A.C., Pincerato K.M., et al. Sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy. Eur J Surg Oncol 2003, 29:118-120.
73. Haid A., Koeberle-Wuehrer R., Offner F., et al. Clinical usefulness and perspectives of sentinel node biopsy in the management of breast cancer. Chirurg 2003, 74:657-664.
74. Kang S.H., Kim S.K., Kwon Y., et al. Decreased identification rate of sentinel lymph node after neoadjuvant chemotherapy. World J Surg 2004, 28:1019-1024.
75. Shimazu K., Tamaki Y., Taguchi T., et al. Sentinel lymph node biopsy using periareolar injection of radiocolloid for patients with neoadjuvant chemotherapy-treated breast carcinoma. Cancer 2004, 100:2555-2561.
76. Lang J.E., Esserman L.J., Ewing C.A., et al. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. J Am Coll Surg 2004, 199:856-862.
77. Patel N.A., Piper G., Patel J.A., et al. Accurate axillary nodal staging can be achieved after neoadjuvant therapy for locally advanced breast cancer. Am Surg 2004, 70(8):696-699.
78. Aihara T., Munakata S., Morino H., et al. Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy. A pilot study. J Surg Oncol 2004, 85:77-81.
79. Kinoshita T., Takasugi M., Iwamoto E., et al. Sentinel lymph node biopsy examination for breast cancer patients with clinically negative axillary lymph nodes after neoadjuvant chemotherapy. Am J Surg 2005, 194(1):135-136.
80. Tanaka Y., Maeda H., Ogawa Y., et al. Sentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy. Oncol Rep 2006, 15:927-931.
81. Tausch C., Konstantiniuk P., Kugler F., et al. Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Group. Ann Surg Oncol 2008, 15(12):3378-3383.
82. Gimbergues P., Abrial C., Durando X., et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann Surg Oncol 2008, 15(5):1316-1321.
83. Hino M., Sano M., Sato N., et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in a patient with operable breast cancer. Surg Today 2008, 38:585-591.
84. Classe J.-M., Bordes V., Campion L., et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 2008, 27(5):726-732.
85. Schwartz G.F., Tannelbaum J.E., Jernigan A.M., et al. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast. Cancer 2010, 116(5):1243-1251.
86. Guiliano A.E., Haigh P.I., Brennan M.B., et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000, 18:2553-2559.
87. Schrenk P., Hatzl-Griesenhofer M., Shamiyeh A., et al. Follow-up of sentinel node negative breast cancer patients without axillary lymph node dissection. J Surg Oncol 2001, 77:165-170.
88. Roumen R.M., Kujit G.P., Liem I.H., et al. Treatment of 100 patients with sentinel node negative breast cancer without further axillary dissection. Br J Surg 2001, 88:1639-1643.
89. Veronesi U., Galimberti V., Zurrida S., et al. Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer. Eur J Cancer 2001, 37:454-458.
90. Chung M.A., Steinhoff M.M., Cady B. Clinical axillary recurrence after a negative sentinel node biopsy. Am J Surg 2002, 184:310-314.
91. Badgwell B.D., Povoski S.P., Abdessalam S.F., et al. Patterns of recurrence after sentinel lymph node biopsy for breast cancer. Ann Surg Oncol 2003, 10:376-380.
92. Blanchard D.K., Donohue J.H., Reynolds C., et al. Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch Surg 2003, 138:482-487.
93. Veronesi U., Paganelli G., Viale G., et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003, 349(6):546-553.
94. Reitsamer R., Peintiger F., Prokop E., et al. 200 sentinel lymph node biopsies without axillary lymph node dissection. No axillary recurrences after a 3-year follow-up. Br J Cancer 2004, 90:1551-1554.
95. Naik A.M., Fey J.V., Gemignani M., et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection. Ann Surg 2004, 240:462-468.
96. Imoto S., Wada N., Murakami K., et al. Prognosis of breast cancer patients treated with sentinel node biopsy in Japan. Jpn J Clin Oncol 2004, 34:452-456.
97. Torrenga H., Fabry H., van der Sijp J.R., et al. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis. J Surg Oncol 2004, 88:4-7.
98. Zavagno G., Carcoforo P., Franchini Z., et al. Axillary recurrence after negative sentinel lymph node biopsy without axillary dissection: a study on 479 breast cancer patients. Eur J Surg Oncol 2005, 31(7):715-720.
99. Langer I., Marti W.R., Guller U., et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases. Ann Surg 2005, 241(1):152-158.
100. Snoj M., Bracko M., Zagar I. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node. Croat Med J 2005, 46(3):377-381.
101. Swenson K.K., Mahipal A., Nissen M.J., et al. Axillary disease recurrence after sentinel lymph node dissection for breast carcinoma. Cancer 2005, 104:1834-1839.
102. Smidt M.L., Janssen C.M., Kuster D.M., et al. Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance. Ann Surg Oncol 2001, 12:29-33.
103. Sanjuan A., Vidal-Sicart S., Zanon g, et al. Clinical axillary recurrence after sentinel node biopsy in breast cancer: a follow-up study of 200 patients. Eur J Nucl Med Mol Imaging 2005, 32(8):932-936.
104. Palesty J.A., Foster J.M., Hurd T.C., et al. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer. J Surg Oncol 2006, 93(2):129-132.
105. Rosing D.K., Dauphine C.E., Perla V.M., et al. Axillary regional recurrence after sentinel lymph node biopsy for breast cancer. Am Surg 2006, 72:939-942.
106. Domenech A., Benitez A., Bajen M.T., et al. Patients with breast cancer and negative sentinel lymph node biopsy without additional axillary lymph node dissection: a follow-up study of up to 5 years. Oncology 2007, 72(1-2):27-32.
107. Takei H., Suemasu K., Kurosumi M., et al. Recurrence after sentinel lymph node biopsy with or without axillary lymph node dissection in patients with breast cancer. Breast Cancer 2007, 14(1):16-24.
108. Bergkvist L., de Boniface J., Jonsson P.-E., et al. Axillary recurrence rate after negative sentinel node biopsy in breast cancer: three-year follow-up of the Swedish multicenter cohort study. Ann Surg 2008, 247(1):150-156.
109. Poletti P., Fenaroli P., Milesi A., et al. Axillary recurrence in sentinel lymph node negative breast cancer patients. Ann Oncol 2008, 19(11):1842-1846.